ArticleRespiratory medicine case reports2026
Severe hyperkalemia and muscle weakness in HIV-associated
Article in Respiratory medicine case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-dose trimethoprim-sulfamethoxazole (TMP-SMX) combined with corticosteroids is the first-line treatment for severe Case presentation: We report a 56-year-old male with advanced HIV (CD4: 14 cells/μL) and type 2 diabetes mellitus, treated for PJP with TMP-SMX 20 mg/kg/day and methylprednisolone 80 mg/day. On day 10 of treatment, the patient developed severe muscle weakness and life-threatening hyperkalemia (8.2 mmol/L) unresponsive to medical management, requiring emergency intermittent hemodialysis (IHD). After one hemodialysis session and switching to clindamycin-primaquine, potassium levels normalized within 2 days, and muscle weakness gradually improved and resolved after 4 days. The patient was discharged in a stable condition after 21 days of treatment. Conclusion: This case represents a rare clinical complication with extremely severe hyperkalemia (8.2 mmol/L) accompanied by muscle weakness, likely due to the synergistic effect of hyperkalemia and steroid myopathy. Hemodialysis is an effective and safe intervention for hyperkalemia unresponsive to medical management. Close monitoring of electrolytes and muscle function is crucial in patients receiving high-dose TMP-SMX in combination with corticosteroids, particularly during the first 10 days of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.